Labcorp: The Order, the Blood Draw and the Bill

Labcorp fraud settlements include a $14.5 million resolution in July 2026 over medically unnecessary urine drug testing allegations and a $19 million resolution over allegations that its blood-draw services helped sustain paid referrals to other laboratories. For someone who draws blood, handles requisitions or reconciles healthcare bills, the details matter more than the settlement headline: who did the work, who received the money and what the payer was told.

Laboratory Corporation of America is a national clinical diagnostics company.

Labcorp’s 1996 Settlement Over Predecessors’ Panel Billing

Labcorp, formed the year before, paid $173 million in a 1996 civil settlement to resolve allegations that its predecessor laboratories combined unusual tests with commonly ordered blood panels, according to the federal Health Care Fraud and Abuse Control report for fiscal 1997. A separate $20 million payment went to state Medicaid programs in April 1997.

National Health Laboratories acquired Allied Clinical Laboratories in 1994, then merged with Roche Biomedical Laboratories the following year to form Laboratory Corporation of America. The Labcorp name brought those older laboratory businesses together.

The panel allegations belong to the earlier LabScam enforcement era. Putting an unusual test beside familiar blood work can turn the choice of a routine panel into an order for additional testing. The ordering decision determines what the laboratory can later bill. The later ToxAssure case returns to test selection, with its own product, claims and admitted facts.

The 1997 Mileage Settlement Reached the Drive to the Patient

Labcorp paid the United States $700,000 to resolve allegations that it overstated the mileage of phlebotomists visiting homebound and nursing-home patients. The Justice Department’s June 17, 1997 announcement concerned Florida facilities formerly owned by National Health Laboratories.

The phlebotomists drove their personal vehicles to collect blood, and Medicare reimbursed the laboratory on a per-mile basis. The government alleged that they overstated the miles driven from 1989 through 1996, causing Medicare to pay Labcorp reimbursements it was not entitled to receive. Whistleblowers brought the case.

Here, the disputed claim began before the specimen reached the laboratory. The bill was for the journey to collect it. Someone familiar with the collection route could understand a discrepancy that the test result would never show.

The 2023 Referral Settlement: Labcorp Drew the Blood, Doctors Got the Fee

On February 7, 2023, the Justice Department announced Labcorp’s settlement over blood-draw services and referral payments. The whistleblowers alleged that Labcorp provided phlebotomy services while knowing Health Diagnostic Laboratory and Singulex were paying health care providers processing and handling fees to induce laboratory referrals.

The alleged arrangement divided the work from the payment. According to the whistleblowers’ complaint, a physician received processing fees from HDL and Singulex while a Labcorp-paid worker performed nearly all the processing services, including work on samples destined for those other laboratories.

The physician kept the fee. Labcorp supplied the labor. The complaint alleged that Labcorp’s solution was to keep drawing samples for HDL as long as tests also came to Labcorp. An executive’s words quoted in the complaint put the problem plainly:

Do Doctors Get Kickbacks for Ordering Tests?

The whistleblowers alleged that HDL and Singulex paid physicians fees to send them tests. Their complaint explained how the location of the blood draw helped disguise those referral payments as processing fees:

The complaint also alleged that a physician referred patients to both Labcorp and HDL for duplicative lipid testing on the same day. It described Labcorp as a testing supplier to HDL as well: Labcorp allegedly invoiced HDL for more than $7.6 million in testing from late 2010 until 2015. The laboratories could compete for physician orders while also doing business with each other.

For an insider, those details connect several records that might otherwise sit apart: staffing, processing fees, test orders and laboratory invoices. The arrangement alleged in the complaint paid the physician for work a laboratory employee was doing, while preserving testing business for the laboratories involved.

What Happened to the Health Diagnostic Laboratory Scandal?

HDL and Singulex previously settled their civil liability with the government for a combined $48.5 million. Labcorp’s later settlement addressed its own alleged role in providing phlebotomy services while knowing about the referral payments. The whistleblowers who brought the Labcorp case were allocated approximately $5.6 million from the federal settlement.

The 2023 Department of Defense Case Turned Samples Into Extra Bills

Labcorp agreed to pay $2.1 million to resolve allegations that it overbilled the Department of Defense for genetic testing performed by GeneDx. The March 27, 2023 announcement described a reference-laboratory arrangement: GeneDx performed specialized tests, invoiced Labcorp, and Labcorp invoiced the military.

Labcorp’s contract covered military treatment facilities worldwide. Some genetic tests involved samples from fetuses and parents. According to the former employee’s complaint, Labcorp charged for each sample analyzed when the underlying charge was for the child’s or fetus’s report. What arrived as several specimens became several charges for a test the reference laboratory charged for once.

The complaint quoted an internal email acknowledging the mismatch:

The government alleged double or triple billing, overcharges and charges for which Labcorp could not later locate a military requisition, a GeneDx result or a corresponding GeneDx invoice. The settlement covered alleged conduct from December 2013 through June 2021.

The distinction between a specimen and a report was the money question. A laboratory can handle several family members’ samples for a single reported test. In this case, the whistleblower alleged that Labcorp turned that physical handling into additional billable units. The reference laboratory’s invoice and the bill sent to the military told different stories about the same work.

The 2025 Caris Case and Medicare’s 14-Day Rule

Labcorp and University Health System paid $388,667 to resolve allegations that they delayed physician orders for Caris Life Sciences testing to enable improper Medicare billing. The January 2, 2025 announcement concerned laboratory services at the University of Tennessee Medical Center.

Medicare’s 14-Day Rule affected who received the laboratory’s bill. As the government described the rule for the tests at issue, an order within the window following hospital discharge put the charge through the hospital. Outside the window, the laboratory could bill Medicare directly. The date attached to the order therefore had a financial consequence for the hospital and the laboratory.

The government alleged that University Health System and Labcorp Tennessee held orders, or canceled and resubmitted them, until after the window. The alleged conduct ran from March 2012 through November 2023. University Health System operated the hospital, and Labcorp provided clinical laboratory services through Labcorp Tennessee at its outpatient laboratory.

Caris separately agreed to pay $2.8 million over related conduct nationwide. The local Labcorp and hospital settlement addressed their alleged part in delaying the orders. Holding the order shifted the bill from the hospital to Medicare.

A whistleblower brought the qui tam case and received a 19% share of the settlement.

What Labcorp Admitted About Urine Testing in 2026

Labcorp admitted that it combined preselected presumptive and definitive tests in ToxAssure Comprehensive and billed Medicare Part B for both. The July 15, 2026 settlement announcement set out facts the company accepted responsibility for about how it designed, performed and billed the panel.

From January 1, 2018, through November 22, 2023, Labcorp routinely submitted presumptive and definitive urine-testing claims, including claims under ToxAssure Comprehensive. Presumptive testing detects the presence or absence of drug classes against testing thresholds. Definitive testing identifies individual substances and, where applicable, their concentrations.

Labcorp admitted that ToxAssure Comprehensive combined preselected presumptive tests for some substances with direct-to-definitive testing for others. It ran many of those tests simultaneously for the same patient, on the same date of service, using the same urine sample.

Labcorp used code 80307 for presumptive testing and G0483 for definitive testing. Medicare pays the first at a flat rate regardless of the number of drug classes tested. The second is the highest definitive tier, covering 22 or more drug classes. Labcorp billed Medicare both charges every time it ran the panel. The panel design set the bill.

For several substances sent directly to definitive testing, Labcorp admitted that a presumptive option existed. It performed the definitive tests without first using that option to inform whether definitive testing was necessary for the substance.

The government alleged that the full panel produced medically unnecessary claims for some patients. Labcorp represented that it had stopped billing Medicare for the combination of codes used for this panel. The Justice Department also credited the company under its policy considering disclosure, cooperation and remediation.

Labcorp’s Admitted Urine Testing Facts and Standing Orders

Labcorp’s admitted urine testing facts concern a preselected panel and simultaneous billing. The standing-order comparison is clearest in a separate case: Precision Toxicology’s settlement, where the government expressly alleged that custom profiles functioned as standing orders, generating large test menus without an individualized assessment of patient need.

Both accounts put test selection at the center of the billing question. Labcorp’s admission goes further into what happened to one patient’s specimen: which methods ran together, what information was available when they ran and which charges followed. That is the useful detail for someone who knows the panel configuration or the testing workflow.

When Are Toxicology Tests Unnecessary?

In the Labcorp case, the government alleged unnecessary testing for some patients because of how the full panel operated and was billed. The clinical question is what the selected tests contribute to the particular patient’s care.

The 2014 Pain Physician paper Ethical Perspectives on Urine Drug Screening for Pain Physicians explains that urine testing can monitor medication adherence and provide information about absorption and metabolism. It also describes false-negative and false-positive results and the need to interpret testing in clinical context.

The method selected and the reason for selecting it matter to the patient’s treatment. The billing codes describe what the laboratory charged for. The clinical record explains why the patient needed it.

What Evidence Is Needed to Prove Fraud?

What proves a laboratory fraud case depends on how the orders, work and payments fit together. Our whistleblower experts work through that connection with you.

The documentation is divided between the practice and the laboratory. Under Medicare’s ordering and documentation rules, the ordering clinician keeps the medical-necessity record. The billing laboratory keeps the information it received and documentation that its claim accurately reflects that information. Someone inside the physician’s office may know why a test was ordered. Someone in laboratory billing may know what the claim became.

The Labcorp complaints show the value of bringing those views together. One quoted an executive questioning why a physician received payment for a draw Labcorp performed. Another quoted an email recognizing that the laboratory was charging for each specimen while its supplier charged once. Those are explanations from inside the business of how the money moved.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know How the Laboratory Got Paid

If you saw a physician paid for work your laboratory performed, a family test become several charges or an order held until its billing changed, speak with our whistleblower experts about how the laboratory got paid. We build your strongest laboratory whistleblower case with you and bring in laboratory fraud whistleblower lawyers who understand referral payments, reference-lab contracts and toxicology billing. We stay beside you through the pursuit of the government’s recovery.